IL182903A - Factor viii polypeptide modified with a biocompatible polymer at predefined sites - Google Patents

Factor viii polypeptide modified with a biocompatible polymer at predefined sites

Info

Publication number
IL182903A
IL182903A IL182903A IL18290307A IL182903A IL 182903 A IL182903 A IL 182903A IL 182903 A IL182903 A IL 182903A IL 18290307 A IL18290307 A IL 18290307A IL 182903 A IL182903 A IL 182903A
Authority
IL
Israel
Prior art keywords
factor viii
leu
ser
conjugate
amino acid
Prior art date
Application number
IL182903A
Other languages
English (en)
Hebrew (he)
Other versions
IL182903A0 (en
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL182903(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IL182903A0 publication Critical patent/IL182903A0/en
Publication of IL182903A publication Critical patent/IL182903A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
IL182903A 2004-11-12 2007-05-01 Factor viii polypeptide modified with a biocompatible polymer at predefined sites IL182903A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (2)

Publication Number Publication Date
IL182903A0 IL182903A0 (en) 2007-08-19
IL182903A true IL182903A (en) 2014-09-30

Family

ID=36337298

Family Applications (3)

Application Number Title Priority Date Filing Date
IL182903A IL182903A (en) 2004-11-12 2007-05-01 Factor viii polypeptide modified with a biocompatible polymer at predefined sites
IL232540A IL232540A (en) 2004-11-12 2014-05-11 Factor-site change of viii
IL23443314A IL234433B (en) 2004-11-12 2014-09-02 Site-directed modification of factor viii

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL232540A IL232540A (en) 2004-11-12 2014-05-11 Factor-site change of viii
IL23443314A IL234433B (en) 2004-11-12 2014-09-02 Site-directed modification of factor viii

Country Status (32)

Country Link
US (4) US7632921B2 (OSRAM)
EP (9) EP2363414B1 (OSRAM)
JP (5) JP2008524117A (OSRAM)
KR (7) KR20120136413A (OSRAM)
CN (6) CN101124331B (OSRAM)
AU (1) AU2005304622B2 (OSRAM)
BE (1) BE2019C523I2 (OSRAM)
BR (2) BRPI0517795B8 (OSRAM)
CA (1) CA2586379C (OSRAM)
CY (3) CY1119292T1 (OSRAM)
DK (3) DK1824988T3 (OSRAM)
ES (4) ES2930159T3 (OSRAM)
FR (1) FR19C1031I2 (OSRAM)
HN (1) HN2007015683A (OSRAM)
HR (2) HRP20180481B1 (OSRAM)
HU (5) HUE050542T2 (OSRAM)
IL (3) IL182903A (OSRAM)
LT (5) LT1824988T (OSRAM)
LU (1) LUC00118I2 (OSRAM)
MA (1) MA29663B1 (OSRAM)
MX (3) MX350293B (OSRAM)
NL (1) NL300989I2 (OSRAM)
NO (3) NO20210454A1 (OSRAM)
NZ (1) NZ555032A (OSRAM)
PH (2) PH12014500352B1 (OSRAM)
PL (3) PL1824988T3 (OSRAM)
PT (4) PT1824988T (OSRAM)
RU (1) RU2423380C2 (OSRAM)
SI (4) SI3130601T1 (OSRAM)
UA (1) UA95225C2 (OSRAM)
WO (1) WO2006053299A2 (OSRAM)
ZA (1) ZA200703696B (OSRAM)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
CN101124331B (zh) 2004-11-12 2013-04-24 拜尔健康护理有限责任公司 Fvⅲ的位点定向修饰
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101484576A (zh) * 2006-05-24 2009-07-15 诺沃-诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
EP2532369B1 (en) 2006-12-15 2017-11-01 Baxalta GmbH Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
JP2011503101A (ja) * 2007-11-09 2011-01-27 バクスター・インターナショナル・インコーポレイテッド 修飾された組換え第ｖｉｉｉ因子およびフォンウィルブランド因子ならびにその使用方法
US20130189239A1 (en) * 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
JP5997443B2 (ja) 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
BRPI0913374A2 (pt) * 2008-06-04 2015-11-24 Bayer Healthcare Llc muteínas fviii para tratamento de doença de von willebrand
ES2654336T3 (es) 2008-06-24 2018-02-13 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
EP3620177A1 (en) * 2008-10-17 2020-03-11 Baxalta GmbH Modified blood factors comprising a low degree of water soluble polymer
CN102202684A (zh) * 2008-11-03 2011-09-28 拜耳医药保健有限公司 用于治疗血友病的方法
CA2744340A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
WO2010102886A1 (en) * 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii
RU2495881C2 (ru) * 2009-03-20 2013-10-20 Ханми Холдингс Ко., Лтд. Способ регулирования условий для сайт-специфического связывания полипептида и непептидильного полимера
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第ｖｉｉｉ因子変異体および使用の方法
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2856055T3 (es) 2009-07-27 2021-09-27 Baxalta GmbH Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
BR112012004094A2 (pt) * 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
EP3326643B1 (en) 2009-12-06 2021-04-07 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
PH12012501664A1 (en) * 2010-02-21 2012-10-22 Bayer Healthcare Llc Method for activation and conjugation of biomolecules
PT2558538T (pt) 2010-04-15 2019-10-10 Kodiak Sciences Inc Polímeros contendo zwiterião de elevado peso molecular
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
EP2635297B1 (en) * 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
KR20130125789A (ko) * 2010-12-16 2013-11-19 노보 노르디스크 에이/에스 수성 인자ⅷ 용액
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
EP3808378A1 (en) * 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
PL2717898T3 (pl) 2011-06-10 2019-06-28 Bioverativ Therapeutics Inc. Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
TWI764092B (zh) 2011-07-08 2022-05-11 美商百歐維拉提夫治療公司 因子viii嵌合及雜交多肽，及其使用方法
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
EP3549953A1 (en) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
CN111574632A (zh) 2012-02-15 2020-08-25 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
PE20160121A1 (es) * 2013-03-15 2016-03-03 Bayer Healthcare Llc Formulaciones de factor viii recombinantes
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
TWI629993B (zh) 2013-03-15 2018-07-21 美商生物化學醫療公司 因子ｖｉｉｉ多肽調配物
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
CN105848670A (zh) * 2013-10-22 2016-08-10 Dbv技术公司 通过诱导对血液因子的耐受治疗血友病的方法
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
WO2015107222A1 (en) 2014-01-20 2015-07-23 Octapharma Ag A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3114138B1 (en) * 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
EP3123090A4 (en) 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Lyophilized factor ix formulations
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
JP6665104B2 (ja) 2014-04-10 2020-03-13 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 配合培地粉末製剤および細胞培養用液体培地の調製方法
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
KR20170026580A (ko) 2014-07-02 2017-03-08 씨에스엘 리미티드 변형된 폰 빌레브란트 인자
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
CN107787328B (zh) 2015-05-22 2021-08-06 康诺贝林伦瑙有限公司 用于治疗血友病的截短的血管性血友病因子多肽
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
JP6851381B6 (ja) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 変異切断型フォンウィルブランド因子
SG10201912857XA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated von willebrand factor
KR102219859B1 (ko) * 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
CN109922824A (zh) 2016-11-11 2019-06-21 康诺贝林伦瑙有限公司 用于治疗血友病的截短的冯维勒布兰德因子多肽
AU2017360979A1 (en) 2016-11-16 2019-05-30 Bayer Healthcare Llc Red blood cell targeted factor VIII and method of using the same
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
AU2017366709A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
MX2019009063A (es) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
CN117467019A (zh) 2018-05-18 2024-01-30 郑州晟斯生物科技有限公司 改进的fviii融合蛋白及其应用
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
EP4069269A4 (en) * 2019-12-06 2023-12-27 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU685187B2 (en) 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
EP0788375A2 (en) 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
WO1997001197A1 (en) * 1995-06-21 1997-01-09 Motorola Inc. Method and antenna for providing an omnidirectional pattern
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6077939A (en) * 1996-08-02 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Methods and kits for making polypeptides having a single covalently bound N-terminal water-soluble polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
CN1113656C (zh) * 1997-10-17 2003-07-09 丰收技术股份有限公司 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
MXPA00010241A (es) 1998-04-27 2004-09-06 Opperbas Holding Bv Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DK1129186T4 (da) 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
BR122013003013B8 (pt) 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
EP1183354A2 (en) 1999-05-24 2002-03-06 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
CN1205221C (zh) 2000-09-19 2005-06-08 埃默里大学 修饰的凝血因子ⅷ
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
JP2004529640A (ja) * 2001-03-22 2004-09-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ凝固因子誘導体
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002098454A2 (en) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
CA2450732A1 (en) 2001-06-14 2002-12-27 John H. Griffin Stabilized proteins with engineered disulfide bonds
AU2002337901B2 (en) 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
WO2003087161A1 (en) 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
CA2509260C (en) 2002-12-31 2012-10-02 Nektar Therapeutics Al, Corporation Maleamic acid polymer derivatives and their bioconjugates
EP1578842B1 (en) 2002-12-31 2009-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
WO2004063250A1 (en) 2003-01-06 2004-07-29 Nektar Therapeutics Al, Corporation Thiol-selective water-soluble polmer derivatives
EP2338523B1 (en) 2003-02-26 2024-01-17 Nektar Therapeutics Polymer-factor viii moiety conjugates
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP1626983B8 (en) * 2003-05-12 2010-12-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
TR201907313T4 (tr) 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
WO2005046583A2 (en) 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
AU2004296768B2 (en) 2003-12-03 2010-06-24 University Of Rochester Recombinant factor VIII having increased specific activity
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
CN101124331B (zh) 2004-11-12 2013-04-24 拜尔健康护理有限责任公司 Fvⅲ的位点定向修饰
JP2008534559A (ja) 2005-04-01 2008-08-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 血液凝固ｆｖｉｉｉ類似体
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
BRPI0708832A2 (pt) * 2006-03-31 2011-06-14 Baxter Int construÇço proteinÁcea

Also Published As

Publication number Publication date
EP3130601A1 (en) 2017-02-15
RU2423380C2 (ru) 2011-07-10
JP6109523B2 (ja) 2017-04-05
KR101483917B1 (ko) 2015-01-16
ES2633916T3 (es) 2017-09-26
PT1824988T (pt) 2017-07-21
US20130274445A1 (en) 2013-10-17
WO2006053299A2 (en) 2006-05-18
AU2005304622B2 (en) 2012-03-29
CA2586379C (en) 2012-04-03
MX392760B (es) 2025-03-24
IL182903A0 (en) 2007-08-19
CN101124331B (zh) 2013-04-24
NO20200044A1 (no) 2007-06-27
ZA200703696B (en) 2008-08-27
DK2371856T3 (en) 2022-08-08
PT2371856T (pt) 2022-08-12
KR20120136413A (ko) 2012-12-18
CN103102406B (zh) 2015-05-27
UA95225C2 (ru) 2011-07-25
NO344606B1 (no) 2020-02-10
BR122016022033B1 (pt) 2021-03-02
KR20140091618A (ko) 2014-07-21
LUC00118I1 (OSRAM) 2019-05-13
CN105148287A (zh) 2015-12-16
US7632921B2 (en) 2009-12-15
US20160051633A1 (en) 2016-02-25
PL1824988T3 (pl) 2018-01-31
CN105753968A (zh) 2016-07-13
EP3243833A1 (en) 2017-11-15
DK2363414T3 (da) 2022-08-08
KR101904630B1 (ko) 2018-10-04
CN101124331A (zh) 2008-02-13
BRPI0517795A (pt) 2008-10-21
CY2019024I1 (el) 2019-11-27
EP2371856B1 (en) 2022-05-18
JP2017105773A (ja) 2017-06-15
PL2371856T3 (pl) 2022-08-22
ES2821832T3 (es) 2021-04-27
JP6559642B2 (ja) 2019-08-14
NO345800B1 (no) 2021-08-09
EP3323829A1 (en) 2018-05-23
EP3153181A1 (en) 2017-04-12
HRP20180481A2 (hr) 2018-06-29
KR101468345B1 (ko) 2014-12-03
CY1119292T1 (el) 2018-02-14
IL232540A0 (en) 2014-06-30
HK1182121A1 (en) 2013-11-22
CY1123384T1 (el) 2021-12-31
SI3130601T1 (sl) 2020-11-30
FR19C1031I2 (fr) 2020-06-05
MX2007005466A (es) 2007-10-19
BR122016022033B8 (pt) 2021-05-25
PT2363414T (pt) 2022-08-04
JP6018238B2 (ja) 2016-11-02
HRP20070268B1 (hr) 2018-04-20
NL300989I1 (nl) 2019-05-22
PH12014500352A1 (en) 2015-07-20
NZ555032A (en) 2010-02-26
CN107082806A (zh) 2017-08-22
PL2363414T3 (pl) 2022-09-05
IL232540A (en) 2017-08-31
EP2772500A1 (en) 2014-09-03
PH12019501613A1 (en) 2020-09-14
HRP20070268A2 (en) 2007-09-30
CN103214569B (zh) 2016-12-28
LUC00118I2 (OSRAM) 2019-12-27
EP1824988A2 (en) 2007-08-29
EP3243834A1 (en) 2017-11-15
EP3323829B1 (en) 2020-07-15
US9364520B2 (en) 2016-06-14
CA2586379A1 (en) 2006-05-18
EP2363414A2 (en) 2011-09-07
HN2007015683A (es) 2011-07-11
AU2005304622A1 (en) 2006-05-18
HUE060016T2 (hu) 2023-01-28
JP2017101028A (ja) 2017-06-08
HUS1900026I1 (hu) 2022-04-28
BRPI0517795A8 (pt) 2018-12-26
BRPI0517795B8 (pt) 2021-05-25
HK1117875A1 (en) 2009-01-23
JP6487895B2 (ja) 2019-03-20
US20100081615A1 (en) 2010-04-01
EP3130601B1 (en) 2020-07-15
KR20070110260A (ko) 2007-11-16
FR19C1031I1 (OSRAM) 2019-06-28
EP2363414A3 (en) 2012-03-21
EP1824988B1 (en) 2017-04-19
LT2371856T (lt) 2022-08-25
KR20140019489A (ko) 2014-02-14
LT1824988T (lt) 2017-10-25
BRPI0517795B1 (pt) 2020-03-31
HUE059193T2 (hu) 2022-10-28
EP2371856A3 (en) 2012-03-14
LTPA2019509I1 (lt) 2019-08-26
KR20180110192A (ko) 2018-10-08
EP3243833B1 (en) 2020-06-17
SI1824988T1 (sl) 2017-11-30
US20060115876A1 (en) 2006-06-01
KR20130036780A (ko) 2013-04-12
PH12014500352B1 (en) 2019-09-25
ES2930159T3 (es) 2022-12-07
CN103102406A (zh) 2013-05-15
NO20072997L (no) 2007-06-27
EP1824988A4 (en) 2008-12-31
JP2015134780A (ja) 2015-07-27
JP2013067621A (ja) 2013-04-18
WO2006053299A3 (en) 2006-08-24
BE2019C523I2 (OSRAM) 2025-02-10
KR101243564B1 (ko) 2013-03-27
EP2363414B1 (en) 2022-05-18
IL234433B (en) 2019-11-28
NL300989I2 (nl) 2019-11-28
HUE033776T2 (en) 2018-01-29
MX350293B (es) 2017-09-04
SI2371856T1 (sl) 2022-09-30
CY2019024I2 (el) 2019-11-27
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
ES2930143T3 (es) 2022-12-07
EP2772500B1 (en) 2019-12-25
LT2363414T (lt) 2022-10-25
HK1218718A1 (zh) 2017-03-10
EP2371856A2 (en) 2011-10-05
CN103214569A (zh) 2013-07-24
US9096656B2 (en) 2015-08-04
MA29663B1 (fr) 2008-08-01
RU2007121517A (ru) 2008-12-20
HRP20180481B1 (hr) 2022-02-18
KR20160105928A (ko) 2016-09-07
LT3130601T (lt) 2020-09-10
KR101654011B1 (ko) 2016-09-05
DK1824988T3 (en) 2017-08-07
PT3130601T (pt) 2020-10-01
HUE050542T2 (hu) 2020-12-28
CN105148287B (zh) 2019-07-09
LTC1824988I2 (lt) 2021-02-25
JP2008524117A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
IL182903A (en) Factor viii polypeptide modified with a biocompatible polymer at predefined sites
AU2012203813B2 (en) Site-directed modification of FVIII
AU2016203693B2 (en) Site-directed modification of FVIII
AU2013203348B2 (en) Site-directed modification of FVIII

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed